1. Home
  2. TNXP vs CTW Comparison

TNXP vs CTW Comparison

Compare TNXP & CTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$11.24

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Logo CTW Cayman Class A Ordinary Shares

CTW

CTW Cayman Class A Ordinary Shares

HOLD

Current Price

$2.45

Market Cap

162.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
CTW
Founded
2007
2013
Country
United States
Japan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
162.2M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
TNXP
CTW
Price
$11.24
$2.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
505.8K
21.6K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
N/A
P/E Ratio
N/A
$22.41
Revenue Growth
29.85
N/A
52 Week Low
$9.40
$1.10
52 Week High
$69.65
$3.14

Technical Indicators

Market Signals
Indicator
TNXP
CTW
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
TNXP
CTW

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About CTW CTW Cayman Class A Ordinary Shares

CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.

Share on Social Networks: